Bio-Techne Heads Into Earnings with a Takeover Clock Ticking

Bio-Techne Corporation enters its Q1 FY2027 results on November 6 with an unusual dynamic: the stock is effectively trading as a pending acquisition target, yet shorts are quietly rebuilding and options positioning has shifted more defensive in recent weeks.

The Merck KGaA takeover agreed earlier this year is now the dominant frame for everything else in this note. ORTEX puts the probability of Bio-Techne being deleted from the Russell 1000, the S&P 500, and the Russell 3000 at between 80% and 84%, all driven by the same event. These are forecasts, not confirmed announcements, and all estimated dates point to a March 2027 announcement and trade, with an effective date around March 31. The bull case in the analyst community leans on the deal closing cleanly, with minimal antitrust friction flagged. The bear case is stark: if the acquisition does not close, valuation could revert to a 17x P/E, a very different number from where the stock is today.

Short interest is modest in absolute terms at 4.8% of the free float, but the direction of travel is worth noting. Shorts have grown about 12% over the past month, with the most recent week adding 2.7% to the position. That is not a crowded short by any measure, and the borrow market is as loose as it gets: availability is running above 4,900%, meaning there are roughly 50 shares available to borrow for every one currently lent out, and cost to borrow has dropped sharply over the week to just 0.26%. The lending market is placing no friction on anyone who wants to short this stock. The most plausible read on the rising short interest is deal-risk hedging rather than a directional bet against the business. Options positioning has shifted marginally more cautious too: the put/call ratio at 0.064 is running about 1.5 standard deviations above its 20-day average, though the absolute level remains very low and well inside the past year's range.

The Street has spent the past several months moving to the sidelines. A cluster of downgrades arrived in late June, when Citigroup, TD Cowen, Benchmark, Stephens, and William Blair all cut to neutral-equivalent ratings. Wells Fargo followed in August, downgrading to Equal-Weight while raising its target to $73. RBC Capital made a similar move in July, stepping from Outperform to Sector Perform. The consensus is now a unanimous hold across 13 analysts, with a mean price target of $73, roughly in line with where the stock is trading at $72.66. That target convergence around the current price tells its own story: the Street is essentially pricing the stock to the deal rather than to a standalone business case. On valuation, the trailing PE is around 32x and EV/EBITDA near 23x, both drifting modestly lower over the past month as the share price has flatlined.

One detail from the alternative data layer is worth carrying: Wikipedia attention for Bio-Techne is running 2.4 standard deviations above its own 90-day average, a signal ORTEX describes as retail attention, not a revenue indicator. Separately, the buyback data from SEC EDGAR filings shows the company spent about $42 million on share repurchases in Q2, down 58% on the same quarter a year earlier. No alt data dataset for Bio-Techne has been measured to lead its reported figures, so neither reading should be read as pointing to the upcoming print.

Insider activity over the past 90 days nets to zero on a share basis. The trades on record are all compensation mechanics: option exercises followed by tax-withholding sales from directors and officers in August and September. No discretionary open-market buying or selling by C-suite figures is visible in the ORTEX EDGAR data for the period.

The largest holder on the register is BlackRock with roughly 9% of shares. FMR (Fidelity) added nearly 4.9 million shares to reach 8.1%, a notable build disclosed in its most recent 13G filing. T. Rowe Price's 13G register shows its stake falling from 5.6% to 2.2%, a significant reduction, though as with all 13D/G disclosures, stakes are as last filed and positions may have moved further since.

The November 6 earnings call is therefore less about what the quarter looks like and more about what management says on deal progress, timeline, and any regulatory developments. Past reaction data from recent prints shows the stock gained 2.8% on the day of its September result before giving back 11% over the following week, while the May print produced a 10% one-day drop and a 21% five-day loss. The deal premium is the cushion that has changed the calculus since then, and how that cushion holds through and after Thursday's release is the number to watch.